These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 12584067)

  • 1. The use of the Ego Impairment Index across the schizophrenia spectrum.
    Perry W; Minassian A; Cadenhead K; Sprock J; Braff D
    J Pers Assess; 2003 Feb; 80(1):50-7. PubMed ID: 12584067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Ego Impairment Index and schizophrenia: a validation study.
    Perry W; Viglione D; Braff D
    J Pers Assess; 1992 Aug; 59(1):165-75. PubMed ID: 1512674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Refinements in the Rorschach Ego Impairment Index incorporating the human representational variable.
    Viglione DJ; Perry W; Meyer G
    J Pers Assess; 2003 Oct; 81(2):149-56. PubMed ID: 12946921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Rorschach Ego Impairment Index in heterogeneous psychiatric patients.
    Adrian C; Kaser-Boyd N
    J Pers Assess; 1995 Dec; 65(3):408-14. PubMed ID: 8609582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurocognitive functioning as intermediary phenotype and predictor of psychosocial functioning across the psychosis continuum: studies in schizophrenia and bipolar disorder.
    Jabben N; Arts B; van Os J; Krabbendam L
    J Clin Psychiatry; 2010 Jun; 71(6):764-74. PubMed ID: 20122370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Meta-Analysis of the relationship between the Rorschach Ego Impairment Index (EII) and psychiatric severity.
    Diener MJ; Hilsenroth MJ; Shaffer SA; Sexton JE
    Clin Psychol Psychother; 2011; 18(6):464-85. PubMed ID: 20941796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Personality traits in schizophrenia and related personality disorders.
    Camisa KM; Bockbrader MA; Lysaker P; Rae LL; Brenner CA; O'Donnell BF
    Psychiatry Res; 2005 Jan; 133(1):23-33. PubMed ID: 15698674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Rorschach Schizophrenia Index (SCZI): an examination of reliability, validity, and diagnostic efficiency.
    Hilsenroth MJ; Fowler JC; Padawer JR
    J Pers Assess; 1998 Jun; 70(3):514-34. PubMed ID: 9760741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A psychometric evaluation of the Rorschach comprehensive system's perceptual thinking index.
    Dao TK; Prevatt F
    J Pers Assess; 2006 Apr; 86(2):180-9. PubMed ID: 16599792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distractibility in schizophrenia: state and trait aspects.
    Spring B; Lemon M; Weinstein L; Haskell A
    Br J Psychiatry Suppl; 1989 Jul; (5):63-8. PubMed ID: 2605025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Vulnerability to schizophrenia: neuropsychological performance and schizotypal personality traits].
    Laurent A; Halim V; Sechier P; Daumal M; Foussard N; Dumas P; Daléry J; d'Amato T
    Encephale; 2001; 27(2):173-9. PubMed ID: 11407270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing disturbed thinking and cognition using the Ego Impairment Index in older schizophrenia patients: paranoid vs. nonparanoid distinction.
    Auslander LA; Perry W; Jeste DV
    Schizophr Res; 2002 Jan; 53(3):199-207. PubMed ID: 11738533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autochthonous experience, heightened awareness, and perception distortion in patients with schizophrenia: a symptomatological study.
    Honda T; Suzuki H; Iwai K; Fujiwara Y; Kawahara H; Kuroda S
    Psychiatry Clin Neurosci; 2004 Oct; 58(5):473-9. PubMed ID: 15482577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical status of at-risk individuals 5 years later: further validation of the psychometric high-risk strategy.
    Gooding DC; Tallent KA; Matts CW
    J Abnorm Psychol; 2005 Feb; 114(1):170-5. PubMed ID: 15709824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Rorschach Ego Impairment Index: prediction of treatment outcome in a child psychiatric population.
    Stokes JM; Pogge DL; Powell-Lunder J; Ward AW; Bilginer L; DeLuca VA
    J Pers Assess; 2003 Aug; 81(1):11-9. PubMed ID: 12842799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of new and revised Rorschach measures of schizophrenic functioning in a Serbian clinical sample.
    Dzamonja-Ignjatovic T; Smith BL; Djuric Jocic D; Milanovic M
    J Pers Assess; 2013; 95(5):471-8. PubMed ID: 23844937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Symptoms of DSM IV borderline personality disorder in a nonclinical population of adolescents: study of a series of 35 patients].
    Chabrol H; Chouicha K; Montovany A; Callahan S
    Encephale; 2001; 27(2):120-7. PubMed ID: 11407263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [French translation of the Chapman Social and Physical Anhedonia Questionnaire: validation of the French translation in controls and schizophrenic patients].
    Assouly-Besse F; Dollfus S; Petit M
    Encephale; 1995; 21(4):273-84. PubMed ID: 7588166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incremental validity of the Ego Impairment Index: a re-examination of Dawes (1999).
    Perry W
    Psychol Assess; 2001 Sep; 13(3):403-7. PubMed ID: 11556278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thought disorder. A function of schizophrenia, mania, or psychosis?
    Marengo J; Harrow M
    J Nerv Ment Dis; 1985 Jan; 173(1):35-41. PubMed ID: 3965610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.